Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Solid Tumors × Panitumumab × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Colorectal Neoplasms 56 Colonic Neoplasms 17 Rectal Neoplasms 10 Esophageal Neoplasms 9 Neoplasm Metastasis 7 Pancreatic Neoplasms 6 Cholangiocarcinoma 6 Breast Neoplasms 6 Neoplasms 5 Colorectal Cancer Metastatic 5 Carcinoma, Non-Small-Cell Lung 5 Squamous Cell Carcinoma of Head and Neck 4 Head and Neck Neoplasms 4 Triple Negative Breast Neoplasms 3 Ovarian Neoplasms 3 Carcinoma, Squamous Cell 3 Adenocarcinoma Of Esophagus 3 Urinary Bladder Neoplasms 2 Stomach Neoplasms 2 Recurrence 2 Prostatic Neoplasms 2 Lung Neoplasms 2 Inflammatory Breast Neoplasms 2 Glioma 2 Gastrointestinal Neoplasms 2 Carcinoma 2 Adenocarcinoma 2 Unspecified Adult Solid Tumor, Protocol Specific 1 Solid Tumors 1 Serotonin Syndrome 1

Interventions

Sunitinib 4 Cyclophosphamide 4 Capecitabine 4 Bevacizumab 4 pazopanib 3 Topotecan 3 Paclitaxel 3 Docetaxel 3 Carboplatin 3 temsirolimus 2 liposomal doxorubicin 2 fludarabine 2 Sorafenib 2 Panobinostat 2 NVP-BKM120 2 Lapatinib 2 Irinotecan 2 Immune Checkpoint Inhibitors 2 Gemcitabine 2 Everolimus 2 Erlotinib Hydrochloride 2 Doxorubicin 2 Bortezomib 2 vadimezan 1 spartalizumab 1 somatostatin receptor 2 1 selinexor 1 selicrelumab 1 perifosine 1 pegylated granulocyte colony-stimulating factor 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00586443 2014-11-19

BEP

Duke University

Phase 1 Completed

Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡